Richard C. Duke

Dr. Duke is a biotechnology executive, inventor, biomedical researcher, and serial entrepreneur with more than 20 years of experience in building, financing, and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions.

Dr. Duke is currently the founder and chief scientific officer of the Colorado Institute for Drug, Device, and Diagnostic Development (CID4). Dr. Duke is a co-scientific founder and former chief executive officer of GlobeImmune (NASD: GBIM) and was involved in the formation and/or management of Newellink, ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, MenoGeniX, PeptiVir, and Aurora Oncology. These Colorado-based companies have raised more than $200 million in financing and have multiple products in phase I and II clinical trials. Dr. Duke has more than 30 years of experience in biomedical research and is a tenured faculty member in the Department of Medicine at the University of Colorado Denver. He has more than 70 research publications and his work on apoptosis was recognized as the cover article of “Scientific American”. He is a graduate of McGill University (B.Sc. and M.Sc.) and the University of Colorado (Ph.D.).